.Effect of N-acetylcysteeine on non-alcoholic fatty liver disease
Phase 3
Recruiting
- Conditions
- Non-alcoholic fatty liveron-alcoholic fatty liver_N acetyle cysteine.
- Registration Number
- IRCT20201220049772N1
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
Patients with non-alcoholic fatty liver disease based on diagnostic criteria
Age 25 to 75 years
No smoking
Exclusion Criteria
Having any acute and active infection
Consumption of any kind of supplement (vitamins, minerals, etc.) by the patient during the last 3 months
Severe renal failure (eGFR less than 30 ml / min)
Severe liver failure
Diabet mellitus
Hyperlipidemia requires medical treatment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome variables in this study include insulin resistance. Timepoint: Calculation of insulin resistance at the beginning of the study and eight weeks after starting N acetylcysteine. Method of measurement: The Index-HOMA formula is used to calculate insulin resistance, which is the product of serum insulin (ml /µIU) multiplied by fasting plasma glucose (dL / mg) divided by 405.
- Secondary Outcome Measures
Name Time Method Serum levels of liver enzymes. Timepoint: At the beginning of the study and eight weeks after starting to take N-acetylcysteine. Method of measurement: Enzymatically using an autoanalyzer.;Metabolic profiles (fasting plasma glucose, fasting serum cholesterol, fasting serum triglyceride). Timepoint: At the beginning of the study and eight weeks after starting to take N-acetylcysteine. Method of measurement: Serum total cholesterol, C-LDL, C-HDL and triglyceride concentrations are measured enzymatically using an autoanalyzer. Determination of fasting blood sugar using glucose oxidase / peroxidase method Pars Azmoun Company, Tehran, Iran).